Immune Response News and Research

RSS

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.

12 Jul 2010

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.

8 Jul 2010

Research findings link some autoimmune disorders with cancer

Patients with a certain type of scleroderma may get cancer and scleroderma simultaneously, Johns Hopkins researchers have found, suggesting that in some diseases, autoimmunity and cancer may be linked.

8 Jul 2010

Researchers develop computer program to accurately simulate protein folding

All proteins self-assemble in a fraction of the blink of an eye, but it can take a long time to mimic the process. And there has been no guarantee of success, even with the most powerful computers - until now.

8 Jul 2010

Trigger that induces B cells to produce early, effective antibody response discovered

Researchers at National Jewish Health have discovered a trigger that induces B cells to produce effective and long-lived antibodies early in the immune response. They found that a molecule that binds toll-like receptors doubles the early antibody response to an antigen, and shifts it to a more effective, IgG form.

7 Jul 2010

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.

7 Jul 2010

A20 protein plays protective role in diseases associated with chronic bowel inflammation: Scientists

Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs.

5 Jul 2010

UCLA study highlights traffic-related asthma flares in urban areas

A new academic study led by UCLA scientists has found that even brief exposure to ultrafine pollution particles near a Los Angeles freeway is potent enough to boost the allergic inflammation that exacerbates asthma.

2 Jul 2010

Mice study may provide new insight on human pregnancies

The concept of pregnancy makes no sense-at least not from an immunological point of view. After all, a fetus, carrying half of its father's genome, is biologically distinct from its mother. The fetus is thus made of cells and tissues that are very much not "self"-and not-self is precisely what the immune system is meant to search out and destroy.

2 Jul 2010

Research findings suggest new treatment approach to improve corneal transplants

Although it is already one of medicine's most successful transplant procedures, doctors continue to seek ways to improve corneal transplants. Now, for the first time, a team of German and British researchers have confirmed that failure and rejection of transplanted corneas are more likely in patients whose eyes exhibit abnormal vessel growth, called corneal neovascularization, prior to surgery.

1 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

Mirna Therapeutics announced today publication of new results in the journal Cancer Research demonstrating proof of concept that the systemic delivery of tumor suppressor microRNAs (miRNA) inhibits tumor growth by restoring the proper regulatory pathways required for cell cycle arrest and apoptosis.

30 Jun 2010

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

30 Jun 2010

Ovarian transplant procedure increases lifespan, restores fertility in aging mice

Scientists have discovered that when they transplant ovaries from young mice into aging female mice, not only does the procedure make the mice fertile again, but also it rejuvenates their behaviour and increases their lifespan. The question now is: could ovarian transplants in women have the same effect?

29 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

An immune cell known to cause chronic inflammation in autoimmune disorders has been identified as a possible culprit in low back pain associated with herniated discs, according to doctors at Duke University Medical Center.

29 Jun 2010

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

29 Jun 2010

IAVI announces Japanese pledge of $10M for AIDS vaccine research and development

The International AIDS Vaccine Initiative (IAVI) announced today that the Government of Japan pledged a US$10 million grant to support AIDS vaccine research and development over the next five years. The grant, which will be channeled through a newly established World Bank trust fund, is the first of its kind from the Japanese government to IAVI.

28 Jun 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Human Genome Sciences, Inc. today announced the presentation of additional results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Vancouver at the 9th International Congress on Systemic Lupus Erythematosus on Friday and Saturday, June 25-26.

28 Jun 2010

IDRI signs Research Collaboration Agreement with PATH

Two global health non-profit organizations headquartered in Seattle, Washington, the Infectious Disease Research Institute and PATH, have entered into a Research Collaboration Agreement to evaluate novel adjuvants for their ability to enhance the immune response of pandemic influenza vaccines in development. The collaboration supports the goal of PATH's influenza vaccine project to advance the development of promising new influenza vaccines focusing on novel technologies that can be accessible, affordable, and available to people in low-resource countries in a global outbreak.

25 Jun 2010

Immune Response News and Research

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Research findings link some autoimmune disorders with cancer

Researchers develop computer program to accurately simulate protein folding

Trigger that induces B cells to produce early, effective antibody response discovered

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

A20 protein plays protective role in diseases associated with chronic bowel inflammation: Scientists

UCLA study highlights traffic-related asthma flares in urban areas

Mice study may provide new insight on human pregnancies

Research findings suggest new treatment approach to improve corneal transplants

Bortezomib may offer hope for treating inflammatory diseases: New research

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

Ovarian transplant procedure increases lifespan, restores fertility in aging mice

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

IAVI announces Japanese pledge of $10M for AIDS vaccine research and development

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

IDRI signs Research Collaboration Agreement with PATH

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News